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SULTS: Compared to patients treated with ziprasidone,
data seem to suggest that olanzapine patients had a
higher response rate, a higher incidence of weight gain,
and a lower incidence of QTc prolongation. Total medi-
cal cost was higher for ziprasidone patients when the
medication cost of ziprasidone was assumed to be more
than half the price than that of olanzapine. The olanza-
pine group’s costs were more sensitive to changes in drug
costs, whereas the ziprasidone group’s costs were more
sensitive to the response rate of the medication used for
those patients not responsive to ziprasidone. CONCLU-
SIONS: Compared to ziprasidone patients, olanzapine
patients may have a higher response rate, a higher inci-
dence of weight gain, and a lower incidence of QTc pro-
longation, with lower total costs as long as ziprasidone is
more than half the price of olanzapine.
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OBJECTIVES: We report on trends in medication adher-
ence for patients who received conventional and atypical
antipsychotics under routine outpatient care during a
9-month period in 1998–9. METHODS: Refill records
were analyzed for over 25,000 patients at a national re-
tail pharmacy chain. Persistence was defined as a pa-
tient’s possession of medication at 30 day intervals from
a patient’s initial prescription. Persistence was taken as a
proxy for medication adherence. RESULTS: The percent-
age of patients adhering to therapy at nine months was
44.4% for atypical agents; 47.6% for conventional
agents; and 71.1% for clozapine. CONCLUSIONS: Im-
proved clozapine adherence was associated with a closely
supervised medication administration process that en-
sured patient tracking and frequent and sustained pa-
tient-provider contact. Atypical agents, with their im-
proved side-effect profile relative to conventional agents,
were not associated with better adherence. These results
suggest that improved side-effect profiles alone may not
insure higher levels of medication adherence and that im-
proved medication administration processes may facili-
tate higher levels of outpatient medication adherence for
patients with major mental illness.
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OBJECTIVE: Comparative cost-effectiveness was as-
sessed in an open-label, randomized trial (QUEST) that
compared the efficacy and safety of quetiapine with ris-
peridone in a outpatient population with schizophrenia
or other psychotic disorders. METHOD: Based on the
overall Positive And Negative Syndrome Scale (PANSS)
scores, patients in QUEST were categorized into one of
three health states—mild (PANSS 74.5), moderate
(PANSS 74.5 and 106.5), or severe (PANSS score
106.5)—at baseline and at 2 months and 4 months.
Utilities and expected utilities from baseline were calcu-
lated. RESULTS: At baseline, 297 (54.0%), 206 (37.5%),
and 47 (8.5%) quetiapine patients, had mild, moderate
or severe symptoms compared to 102 (59.0%), 55
(31.8%), and 16 (9.2%) in the risperidone group. For pa-
tients in the mild or moderate states at baseline, improve-
ments were seen in both treatment groups. For severe pa-
tients, more quetiapine patients improved: 21.2% versus
7.7% in the mild state and 60.6% versus 30.8% in the
moderate state (p  0.020) at 2 months and 46.9% ver-
sus 0.0% in the mild state and 40.6% versus 62.5% in
the moderate state (p  0.023) at 4 months. Overall,
when weighted by utilities, quetiapine treated patients at-
tained greater gains in health state utilities at each follow-
up visit for the mild (0.61  0.069), moderate (0.36 
0.073) and severe (0.29  0.071) states. At 2-months,
quetiapine patients enjoyed a gain of 0.239 from their
baseline level compared to 0.175 for the risperidone
group. At 4-months, the gains were 0.329 versus 0.184
for the quetiapine and risperidone groups (p  0.05). Av-
erage daily doses were 253.9mg quetiapine and 4.4mg
risperidone, yielding average daily costs to US consumers
of $6.38 and $7.85. At average retail costs to consumers
in the US, quetiapine reduces costs by $1.47/day or
$536.55 annually. CONCLUSION: Patients with schizo-
phrenia or other psychotic disorders, treatment with que-
tiapine resulted in significant effectiveness and cost sav-
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CONTEXT: So-called chronic depression, a limiting fac-
tor in terms of social reinsertion, must be diagnosed to
enable its management and to prevent a decline towards
a profound, desocialised state. OBJECTIVE: To deter-
mine the incidence of depression in populations of the
homeless, who are users of the Samu Social de Paris—
Paris Social Emergencies Unit—(SSP). METHOD: Once
an individual had been assessed and a response found to
his or her need, it was suggested that patients calling the
SSP free-phone number should agree to complete the
CES-D questionnaire. Developed in the US by Randloff
(1977), this questionnaire enables the detection of de-
pressive symptoms in a given population. Its use over the
150 Abstracts
telephone has been validated. RESULTS: Mean age: 43
years. Sex ratio: 84% men, 16% women, this being in
line with the ratio of users of the SSP. In 54% of our sam-
ple, the period of homelessness was longer than 2 years;
92% were single, 64% had maintained contacts with
their family and 36% declared they had no income. 70%
of those questioned had a score of 17 or higher on the
CES-D scale, indicative of depressive symptoms, mean
score: 22.4; the prevalence of possible depression was
69% and that of probable was 60%. Although no signifi-
cant difference was seen in terms of the duration of
homelessness, two peaks were nonetheless observed: at
28 for those on the street for more than one month and
less than 6 months, and 22.8 for those homeless for more
than two years. CONCLUSION: By “turning the spot-
light” on a poorly understood population, this study pro-
vides relevant results, which demonstrate the need to act
very rapidly to help these populations living in consider-
able need, before the homeless sink into a state of perma-
nent poverty.
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OBJECTIVES: This study compares the one-year direct
schizophrenia-related treatment costs, mental health care
costs and total health care costs of uncontrolled schizo-
phrenia patients initiated on olanzapine versus risperi-
done. METHODS: The integrated medical and pharmacy
claims of a large, geographically diverse, commercially
insured population were used to conduct this analysis.
Patients who initiated treatment with either olanzapine
or risperidone and had one inpatient or two outpatient
services for schizophrenia within 30 days prior to initia-
tion of drug of interest were included in this analysis.
Treatment course and associated schizophrenia-related,
mental health care and total health care costs during the
subsequent 12-month period were examined using uni-
variate and multivariate methods. RESULTS: Four hun-
dred thirty-one (431) patients initiated on risperidone
and 142 initiated on olanzapine met inclusion criteria.
The mean dose was 4.34 and 11 for risperidone and
olanzapine patients, respectively. During the one-year pe-
riod after initiation of drug of interest, olanzapine pa-
tients (compared with risperidone patients) were less
likely to be hospitalized and had shorter mean length of
hospital stays for schizophrenia-related causes, mental
health care causes and all causes. Although pharmaceuti-
cal costs were significantly higher, medical costs were sig-
nificantly lower for patients on olanzapine compared to
those on risperidone. Univariate and multivariate analy-
ses (controlling for potential confounding factors such as
patient demographics, disease severity and comorbidities)
consistently demonstrated that olanzapine patients had
significantly lower schizophrenia-related costs ($2,839 less,
p  0.05), lower mental health care costs ($3,744 less, p 
0.005) and lower total health care costs ($4,674 less, p 
0.001) than those patients initiated on risperidone. CON-
CLUSIONS: The findings revealed significant differences
between olanzapine and risperidone in the treatment of
uncontrolled schizophrenics in clinical practice. Olanza-
pine patients incurred lower costs (lower schizophrenia-
related, mental health care and total health care costs).
The lower costs were inpatient driven by fewer hospital-
izations and shorter length of hospital stays in the olanza-
pine treatment group.
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OBJECTIVE: To compare health care expenditures of
treatment with SNRIs and SSRIs in depressed patients
with or without anxiety. METHOD: Using administra-
tive claims from the MEDSTAT MarketScan database,
we identified patients with a new episode of depression
enrolled in a participating health plan from 1994 to
1998. Patients included for analysis had both a diagnosis
of depression (ICD-9-CM criteria) and a prescription for
either an SNRI (venlafaxine [n  290], venlafaxine XR
[n  63]) or an SSRI (fluoxetine [n  2854], paroxetine
[n  1772], sertraline [n  2580], fluvoxamine [n 
124]) antidepressant. RESULTS: The SNRIs (n  353)
had lower inpatient non–mental health costs ($206 vs
$472; P  0.02) and lower antidepressant medication
costs ($302 vs $338; P  0.01) compared with the SSRIs
(n  7330). In particular, venlafaxine (n  290) costs
were lower than fluoxetine (n  2854) costs ($281 vs
$395; P  0.05). Among patients with depression and
anxiety, SNRIs (n  219) had lower inpatient non–men-
tal health costs ($273 vs $635; P  0.04) and lower anti-
depressant medication costs ($304 vs $350; P  0.01)
than SSRIs (n  4351). Among depressed patients with-
out anxiety, SNRIs (n  134) had lower inpatient non–
mental health costs ($96 vs $234; P  0.05) and lower
inpatient mental health costs among users of inpatient
mental health services ($2,301 vs $4,847; P  0.02) rela-
tive to SSRIs (n  2979). CONCLUSION: Patients re-
ceiving SNRIs appear to have lower health care expendi-
tures in some areas compared with SSRIs among depressed
patients with or without anxiety. Further research is
needed to determine whether patients treated with SNRIs
can be shown to accrue more favorable economic bene-
fits over time relative to patients treated with SSRIs.
